P. Hingorani

D. Carpentieri, N. Page, P. Hingorani, 2019, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: A phase I/IIa study.

C. Pratilas, B. Geoerger, J. Whitlock, 2018 .

Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

B. Geoerger, J. Whitlock, D. Hargrave, 2019, Clinical Cancer Research.

A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors

C. Pratilas, B. Geoerger, J. Whitlock, 2019, Clinical Cancer Research.

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra‐cranial solid tumors: A Children's Oncology Group Phase I Consortium report

C. Ahern, T. Cripe, B. Weigel, 2015, Pediatric blood & cancer.

A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group

R. Goldsby, K. Janeway, R. Gorlick, 2018, Pediatric blood & cancer.

Disialoganglioside GD2 Expression in Pediatric Rhabdomyosarcoma: A Case Series and Review of the Literature

P. Dickman, Amanda J. Saraf, P. Hingorani, 2019, Journal of pediatric hematology/oncology.

Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force

J. Khan, C. Keller, P. Houghton, 2021, Journal of clinical medicine.

Clinical Application of Prognostic Gene Expression Signature in Fusion Gene–Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group

James R. Anderson, M. Delorenzi, T. Triche, 2015, Clinical Cancer Research.

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors

T. Laetsch, S. Borinstein, L. Mascarenhas, 2021, Cancer medicine.

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.

G. Vassal, C. Márquez-Vega, J. Chisholm, 2020, European journal of cancer.

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group.

James R. Anderson, D. Rodeberg, S. Spunt, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.

C. Bult, P. Meltzer, P. Sorensen, 2016, Cancer genetics.

Utility of bone marrow aspiration and biopsy in initial staging of Ewing sarcoma

Chengcheng Hu, C. Herzog, W. Huh, 2015, Pediatric blood & cancer.

Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children’s Oncology Group

J. Gastier-Foster, J. LaBaer, S. Skapek, 2020, Scientific Reports.

Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group

S. Lessnick, P. Grohar, K. Janeway, 2020, Sarcoma.

Analysis of recurrently protected genomic regions in cell-free DNA found in urine

M. Murtaza, D. V. Von Hoff, K. V. Van Keuren-Jensen, 2021, Science Translational Medicine.

Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+ HLA-DRlo/neg) found in aggressive pediatric sarcoma patients

A. Dietz, M. Gustafson, P. Dickman, 2015, Journal of Immunotherapy for Cancer.

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

John L. Johnson, J. Blattman, P. Hingorani, 2015, Journal of Immunotherapy for Cancer.

Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions

J. Blattman, Lizbeth M. Nieves, P. Dickman, 2015, Journal of immunotherapy.

Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts

C. Guha, Juan Lin, E. Kolb, 2011, Cancer.

Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

Jing Wang, A. Lazar, P. Houghton, 2022, Molecular cancer therapeutics.

ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium

B. Teicher, Malcolm A. Smith, R. Gorlick, 2020, Molecular Cancer Therapeutics.

Metabolic response as assessed by 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

D. Rodeberg, S. Spunt, D. Hawkins, 2020, Cancer medicine.

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force

P. Houghton, J. Yustein, S. Lessnick, 2019, F1000Research.

Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force

Elizabeth Stewart, P. Grohar, P. Houghton, 2021, Pediatric blood & cancer.

Gemcitabine, Docetaxel, and Bevacizumab in Relapsed and Refractory Pediatric Sarcomas

P. Hingorani, A. White-Collins, Masayo Watanabe, 2012, Journal of pediatric hematology/oncology.

Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600–mutant relapsed refractory low-grade glioma.

N. André, B. Geoerger, J. Whitlock, 2018 .

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

S. Baruchel, B. Geoerger, G. Vassal, 2018, European journal of cancer.

Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): Dose-finding and pharmacokinetics (PK).

S. Baruchel, B. Geoerger, G. Vassal, 2016 .

Utility of bone marrow aspiration and biopsy in initial staging of Ewing sarcoma

Chengcheng Hu, C. Herzog, W. Huh, 2015, Pediatric blood & cancer.

R1507, a fully human monoclonal antibody targeting IGF‐1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts

R. Gorlick, P. Hingorani, Wendong Zhang, 2010, Pediatric blood & cancer.

Abstract LB-217: Preclinical evaluation of trastuzumab deruxtecan (T-DXd; DS-8201a), a HER2 antibody-drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC)

P. Houghton, Malcolm A. Smith, R. Gorlick, 2020 .